HUE069018T2 - Anti-CCR8 antitestek - Google Patents

Anti-CCR8 antitestek

Info

Publication number
HUE069018T2
HUE069018T2 HUE22754752A HUE22754752A HUE069018T2 HU E069018 T2 HUE069018 T2 HU E069018T2 HU E22754752 A HUE22754752 A HU E22754752A HU E22754752 A HUE22754752 A HU E22754752A HU E069018 T2 HUE069018 T2 HU E069018T2
Authority
HU
Hungary
Prior art keywords
ccr8 antibodies
ccr8
antibodies
Prior art date
Application number
HUE22754752A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrew Mccluskey
Paustian Amanda Schmidt
Jane Seagal
Julie Wilsbacher
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE069018T2 publication Critical patent/HUE069018T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE22754752A 2021-07-27 2022-07-27 Anti-CCR8 antitestek HUE069018T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27

Publications (1)

Publication Number Publication Date
HUE069018T2 true HUE069018T2 (hu) 2025-02-28

Family

ID=82898810

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE22754752A HUE069018T2 (hu) 2021-07-27 2022-07-27 Anti-CCR8 antitestek

Country Status (27)

Country Link
US (1) US11639393B2 (cg-RX-API-DMAC7.html)
EP (2) EP4491635A3 (cg-RX-API-DMAC7.html)
JP (2) JP7638935B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250135339A (cg-RX-API-DMAC7.html)
CN (1) CN117425677A (cg-RX-API-DMAC7.html)
AR (1) AR126578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022317803A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024837A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220121A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015915A2 (cg-RX-API-DMAC7.html)
DK (1) DK4214240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2995868T3 (cg-RX-API-DMAC7.html)
FI (1) FI4214240T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241561T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069018T2 (cg-RX-API-DMAC7.html)
IL (2) IL319478A (cg-RX-API-DMAC7.html)
LT (1) LT4214240T (cg-RX-API-DMAC7.html)
MX (1) MX2023014154A (cg-RX-API-DMAC7.html)
PL (1) PL4214240T3 (cg-RX-API-DMAC7.html)
PT (1) PT4214240T (cg-RX-API-DMAC7.html)
RS (1) RS66234B1 (cg-RX-API-DMAC7.html)
SA (1) SA523451582B1 (cg-RX-API-DMAC7.html)
SI (1) SI4214240T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400483T1 (cg-RX-API-DMAC7.html)
TW (2) TWI920354B (cg-RX-API-DMAC7.html)
WO (1) WO2023010054A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309516B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US20250019449A1 (en) 2020-03-05 2025-01-16 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Also Published As

Publication number Publication date
CA3220121A1 (en) 2023-02-02
TWI920354B (zh) 2026-04-01
CN117425677A (zh) 2024-01-19
LT4214240T (lt) 2024-11-25
US11639393B2 (en) 2023-05-02
EP4491635A2 (en) 2025-01-15
SA523451582B1 (ar) 2025-04-26
ZA202309516B (en) 2025-03-26
IL307533A (en) 2023-12-01
KR20240067052A (ko) 2024-05-16
AR126578A1 (es) 2023-10-25
HRP20241561T1 (hr) 2025-02-14
JP2025081477A (ja) 2025-05-27
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
DK4214240T3 (da) 2024-11-18
AU2022317803A1 (en) 2023-10-26
EP4491635A3 (en) 2025-04-02
JP7638935B2 (ja) 2025-03-04
JP2023018678A (ja) 2023-02-08
ES2995868T3 (en) 2025-02-11
PL4214240T3 (pl) 2025-01-07
BR112023024837A2 (pt) 2024-02-20
FI4214240T3 (fi) 2024-11-14
EP4214240B1 (en) 2024-10-09
TW202611084A (zh) 2026-03-16
TW202321304A (zh) 2023-06-01
PT4214240T (pt) 2024-11-25
EP4214240A1 (en) 2023-07-26
CO2023015915A2 (es) 2023-12-11
IL307533B2 (en) 2025-08-01
WO2023010054A1 (en) 2023-02-02
SMT202400483T1 (it) 2025-01-14
IL319478A (en) 2025-05-01
MX2023014154A (es) 2024-05-14
RS66234B1 (sr) 2024-12-31
KR102860769B1 (ko) 2025-09-18
IL307533B1 (en) 2025-04-01
KR20250135339A (ko) 2025-09-12

Similar Documents

Publication Publication Date Title
SMT202300397T1 (it) Anticorpi contro sars-cov-2
IL289112A (en) Antibodies against tigit
IL308741A (en) Anti-SIRP-alpha antibodies
GB201905150D0 (en) Ant-ige antibodies
PL4214240T3 (pl) Przeciwciała anty-CCR8
GB202105110D0 (en) Anti-CD73 antibodies
IL284584A (en) Anti-tigit antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
ZA202209699B (en) Novel antibodies
EP4377358A4 (en) NEW ANTI-SIRPA ANTIBODIES
GB202014851D0 (en) SARS-COV-2 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
GB202105933D0 (en) Anti-IL1rap antibody
GB202008022D0 (en) Antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202102227D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies